<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li></ul>The latest update is out from Lixte Biotechnology Holdings ( (LIXT) ). On December 8, 2025, Lixte Biotechnology Holdings held its Annual Meeting where stockholders voted on several key issues. The election of five directors, the ratification of Weinberg &amp; Company, P.A. as the independent accounting firm, and an amendment to increase shares in the 2020 Plan were all approved, reflecting strong shareholder support and positioning the company for continued growth. More about Lixte Biotechnology Holdings Lixte Biotechnology Holdings, Inc. operates in the biotechnology industry, focusing on the development of treatments for serious common diseases such as cancer. The company is involved in the research and development of proprietary compounds that target specific molecular pathways. Average Trading Volume: 112,550 Technical Sentiment Signal: Hold Current Market Cap: $26.4M </div>

LIXT

Lixte Biotechnology Holdings held its Annual Meeting on December 8, 2025, where stockholders approved the election of five directors, ratification of Weinberg & Company, P.A. as the independent accounting firm, and an amendment to increase shares in the 2020 Plan. This reflects strong shareholder support and positions the company for continued growth.

Lixte Biotechnology Holds Annual Meeting, Approves Key Issues